Rheumatology

Older Women With RA at Higher Risk of Developing Hypothyroidism

January 24th 2022, 3:50pm

Article

Women in the study were 3 times more likely to be affected by rheumatoid arthritis (RA) and nearly 4 times more likely to develop hypothyroidism, compared with men.

Frailty Lowers Likelihood of Achieving Comprehensive Disease Control in RA, Study Finds

January 14th 2022, 10:25pm

Article

A study found that frailty reduced the likelihood of comprehensive disease control achievement by patients with rheumatoid arthritis (RA) being treated with a biologic agent.

Study Finds No Link Between Adalimumab, Secukinumab and COVID-19 Vaccine Immune Response

January 12th 2022, 10:35pm

Article

Neither adalimumab nor secukinumab substantially affected a patient’s immune response to the Pfizer COVID-19 vaccine.

COVAX Data Show Similar COVID-19 Vaccine Safety Between General Public, Patients With RMD

January 7th 2022, 6:00pm

Article

The safety profiles of COVID-19 vaccines in patients with inflammatory rheumatic and musculoskeletal disease (RMD) was comparable with patients with non-inflammatory RMD and the general population, according to a new study.

Research Finds MRP8/14 May Be a Biomarker of Systemic Juvenile Idiopathic Arthritis

January 6th 2022, 6:45pm

Article

Investigation into myeloid-related protein 8/14 (MRP8/14) serves as an important next step of translational research to discovering a diagnostic biomarker for systemic juvenile idiopathic arthritis.

Top 5 Most-Read Rheumatology Content of 2021

December 26th 2021, 1:00pm

Article

Readers were most interested in articles about cost of therapy, drug efficacy, and a unique case related to COVID-19.

RA and High Sodium Intake Are Associated With Increased Risk of MACE in Korean Population

December 24th 2021, 9:45pm

Article

A study of the adult Korean population found high salt intake was associated with an increase in major adverse cardiovascular events (MACE) in patients with rheumatoid arthritis (RA).

Secukinumab Approved for Pediatric Patients With ERA, PsA

December 23rd 2021, 3:00pm

Article

Secukinumab is approved for use among patients with enthesitis-related arthritis (ERA) aged 4 years and up, and those with psoriatic arthritis (PsA) who are at least 2 years old.

In Evaluating Rheumatoid Arthritis Treatments, Involving Patients Is Key

December 17th 2021, 6:27pm

Article

Stacy Courtnay is the community network chair for the Arthritis Foundation in Atlanta highlights a report that discusses how understanding patient experiences in RA can shift questions researchers ask.

Review Explains Value of Secukinumab for Children, Adolescents With Moderate to Severe Plaque Psoriasis

December 15th 2021, 1:16pm

Article

With a low number of approved medications for pediatric plaque psoriasis, secukinumab is a valuable new addition to the limited treatment options available.